Bailey Pemberton
4 min read
Organo has seen its share price pull back sharply in recent weeks, yet over a longer horizon the stock still reflects very strong historical gains. That mix of a steep retreat and a powerful five year run puts the spotlight squarely on one question for investors who hold or are eyeing Organo today: whether the current price is in line with the cash the business is expected to generate.
-
Organo has delivered a very large 5 year return of about 4.6x, which raises the question of how much of that rise can be traced back to the durability and trajectory of its cash flows.
-
The company’s ability to convert its operations into steady free cash flow, and to fund future investment without stretching its balance sheet, may support or limit what investors are willing to pay for the shares.
-
What if you looked at Organo through its earnings instead? See why Organo’s 15.4x P/E tells a different valuation story.
The issue now is whether Organo’s recent share price, after both the long run-up and the latest slide, is appropriately aligned with the intrinsic value that its cash flows support.
If you want to stress test this same cash flow question beyond Organo, it can help to compare it with 24 high quality undervalued stocks.
Is Organo Getting Expensive on Cash Flow?
The Discounted Cash Flow (DCF) model here focuses on the cash Organo can return to shareholders over time. Latest twelve month free cash flow sits at about ¥13.3b, and the projections used in the model point to declining free cash flow levels over the coming decade rather than a straight growth story.
Those estimates lean on one analyst forecast out to 2029 and then assume gradually lower free cash flow thereafter, which presents Organo as a mature operator with cash generation that levels off and then eases back. When those future streams are discounted and compared with today’s share price of ¥1,800.00, the DCF output suggests the estimated intrinsic value is meaningfully below where the stock trades today. Find out what Organo could be worth using our Discounted Cash Flow (DCF) estimate.
The Organo Narrative: What Would Justify Today’s Price?
Organo’s valuation puzzle only really starts to come into focus once you spell out the future it would need on growth, margins and earnings for the share price to sit meaningfully above or below where it trades today. This is what Simply Wall St Narratives on the Community page aim to do. Each scenario links a fair value estimate to a specific mix of potential catalysts and risks for Organo, so you can watch over time which version of the story the business is actually tracking.
